Yvonne Hui Sells 582 Shares of Phreesia, Inc. (NYSE:PHR) Stock

Phreesia, Inc. (NYSE:PHR) insider Yvonne Hui sold 582 shares of Phreesia stock in a transaction dated Tuesday, June 10th. The stock was sold at an average price of $28.00, for a total value of $16,296.00. Following the completion of the sale, the insider now owns 31,010 shares of the company’s stock, valued at $868,280. The trade was a 1.84% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Yvonne Hui also recently made the following trade(s):

• On Monday, April 21st, Yvonne Hui sold 993 shares of Phreesia stock. The stock was sold at an average price of $23.04, for a total value of $22,878.72.
• On Tuesday, April 15th, Yvonne Hui sold 314 shares of Phreesia stock. The stock was sold at an average price of $24.04, for a total value of $7,548.56.
• On Tuesday, April 8th, Yvonne Hui sold 1,878 shares of Phreesia stock. The stock was sold at an average price of $23.85, for a total value of $44,790.30.

Phreesia Stock Down 5.6%

Shares of PHR opened at $26.60 on Friday. The business’s 50 day moving average is $24.97 and its 200 day moving average is $25.69. The company has a market capitalization of $1.58 billion, a PE ratio of -18.10 and a beta of 0.68. Phreesia, Inc. has a 12-month low of $17.07 and a 12-month high of $30.53. The company has a current ratio of 1.74, a quick ratio of 1.74 and a debt-to-equity ratio of 0.04.

Phreesia (NYSE:PHR) last issued its earnings results on Wednesday, May 28th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.06. The company had revenue of $115.94 million for the quarter, compared to the consensus estimate of $115.00 million. Phreesia had a negative return on equity of 32.78% and a negative net margin of 20.43%. The firm’s quarterly revenue was up 14.5% on a year-over-year basis. During the same quarter last year, the company earned ($0.05) EPS. Research analysts expect that Phreesia, Inc. will post -1.1 earnings per share for the current fiscal year.

Institutional Trading of Phreesia

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. raised its stake in Phreesia by 2.4% during the 1st quarter. Vanguard Group Inc. now owns 4,936,515 shares of the company’s stock valued at $126,177,000 after purchasing an additional 113,405 shares during the period. Greenhouse Funds LLLP increased its stake in Phreesia by 2.9% in the 1st quarter. Greenhouse Funds LLLP now owns 2,956,910 shares of the company’s stock worth $75,579,000 after acquiring an additional 83,018 shares during the last quarter. Champlain Investment Partners LLC increased its stake in Phreesia by 20.0% in the 1st quarter. Champlain Investment Partners LLC now owns 2,946,489 shares of the company’s stock worth $75,312,000 after acquiring an additional 490,340 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in Phreesia by 108.7% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,644,988 shares of the company’s stock worth $67,606,000 after acquiring an additional 1,377,904 shares during the last quarter. Finally, Franklin Resources Inc. increased its stake in Phreesia by 0.8% in the 4th quarter. Franklin Resources Inc. now owns 1,509,617 shares of the company’s stock worth $37,982,000 after acquiring an additional 11,986 shares during the last quarter. Institutional investors own 92.10% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have issued reports on PHR shares. Needham & Company LLC reissued a “buy” rating and issued a $29.00 target price on shares of Phreesia in a research report on Thursday, March 13th. Canaccord Genuity Group dropped their target price on Phreesia from $35.00 to $34.00 and set a “buy” rating on the stock in a research report on Thursday, May 29th. Truist Financial raised their target price on Phreesia from $34.00 to $35.00 and gave the stock a “buy” rating in a research report on Thursday, May 29th. DA Davidson lowered their price objective on Phreesia from $36.00 to $34.00 and set a “buy” rating on the stock in a research report on Monday, April 14th. Finally, Citigroup reaffirmed a “buy” rating on shares of Phreesia in a research report on Wednesday, May 28th. Twelve investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Phreesia presently has a consensus rating of “Buy” and a consensus price target of $31.64.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.